# China NMPA Drug Inspection - Hebei Qixin Traditional Chinese Medicine Granules and Slices Co., Ltd. - Vinegar-processed Schisandra chinensis

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hebei-qixin-traditional-chinese-medicine-granules-and-slices-co-ltd/b5a4e1bf-c3ac-4cd0-91c9-846660ec1aa6/
Source feed: China

> China NMPA drug inspection for Hebei Qixin Traditional Chinese Medicine Granules and Slices Co., Ltd. published June 04, 2018. Drug: Vinegar-processed Schisandra chinensis. The Ningxia Food and Drug Administration issued an announcement on June 4, 2018, detailing the results of a regional dru

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Ningxia Drug Quality Sampling Inspection Information Announcement (No. 03, 2018)
- Company Name: Hebei Qixin Traditional Chinese Medicine Granules and Slices Co., Ltd.
- Publication Date: 2018-06-04
- Drug Name: Vinegar-processed Schisandra chinensis
- Inspection Finding: The properties of the medicine do not meet the requirements; the manufacturer indicated on the label did not produce this batch of medicine.
- Action Taken: The relevant municipal and county market supervision administrations have conducted investigations and handled the matter in accordance with the law.
- Summary: The Ningxia Food and Drug Administration issued an announcement on June 4, 2018, detailing the results of a regional drug quality sampling inspection. This extensive oversight activity covered 92 batches across 31 varieties, encompassing chemical drugs, traditional Chinese medicines, and decoction pieces. The inspection revealed that seven distinct varieties, representing eight specific batches, failed to meet the required quality standards, primarily those outlined in the Chinese Pharmacopoeia 2015 Edition, Part I.

Significant violations included manufacturer misrepresentation, where the indicated companies, such as Hebei Qixin Traditional Chinese Medicine Granules & Slices Co., Ltd. and Ningxia Mingde Traditional Chinese Medicine Slices Co., Ltd., were found not to have produced the sampled batches of drugs like Eriocaulon buergerianum, Lysimachia christinae, and Safflower. 

Additional quality issues identified included Dioscorea opposita (Ningxia Mingde Traditional Chinese Medicine Slices Co., Ltd.) failing due to excessive total ash content. Two batches of Citron, manufactured by Anhui Shitian Traditional Chinese Medicine Pieces Co., Ltd. and Ningxia Baicaowang Pharmaceutical Co., Ltd., respectively, did not comply with appearance specifications. Safflower (Shaanxi Xiangju Pharmaceutical Group Co., Ltd.) also failed on appearance, total ash, and acid-insoluble ash. The relevant municipal and county market supervision administrations have initiated investigations and legal actions concerning the non-compliant products.

Company: https://www.globalkeysolutions.net/companies/hebei-qixin-traditional-chinese-medicine-granules-and-slices-co-ltd/743c36a8-2b56-4fa6-a05a-00ffafb5ec40/